Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5247-5252

  Tonini, J ^a,b   Thiebaut A ^a,c   Jourdil, J F ^a   Berruyer, A S ^a   Bulabois, C E ^a   Cahn, J Y ^a,c   Stanke Labesque, F ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b University Grenoble Alpes   (France)

^c LABORATOIRE TIMC IMAG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; PREDNISONE;

ADULT; AGE; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; INVASIVE ASPERGILLOSIS; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84866339808     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00815-12     Document Type: Article

References (20)

1. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
2. Bryant AM, Slain D, Cumpston A, Craig M. 2011. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int. J. Antimicrob. Agents 37:266-269.
3. Cornely OA, et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. (Pubitemid 46148777)
4. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222. (Pubitemid 38223535)
5. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin. Infect. Dis. 46:1813-1821.
6. Ezzet F, et al. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220. (Pubitemid 40188942)
7. Filipovich AH, et al. 2005. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11:945-956. (Pubitemid 41754712)
8. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119.
9. Kohl V, et al. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212.
10. Krishna G, et al. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232.
11. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. (Pubitemid 350234311)
12. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
13. Lebeaux D, et al. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob. Agents Chemother. 53: 5224-5229.
14. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. 2010. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin. Pharmacokinet. 49:379-396.
15. Mitsani D, et al. 2012. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob. Agents Chemother. 56:2371-2377.
16. Przepiorka D, et al. 1995. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15:825-828.
17. Thompson GR, III, et al. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
18. Ullmann AJ, et al. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. (Pubitemid 43190980)
19. Ullmann AJ, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. (Pubitemid 46148776)
20. Walsh TJ, et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. (Pubitemid 44968977)